ArticleAsian Pacific journal of cancer prevention : APJCP2025
Doxorubicin Effects Breast Cancer Proliferation via the NEAT1/miR-410-3p Axis.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDoxorubicin (DOX) is an anthracycline derivative, a conversant chemotherapeutic agent, and one of the most influential chemotherapeutic drugs. Long noncoding RNAs (lncRNAs) play a vital role in this process. The current review demonstrates that lncRNAs can function as oncogenic and tumor suppressors and contribute to cancer development and progression. Our study addressed the nuclear-enriched abundant transcript 1 (NEAT1) and the effect of DOX on the regulation of miR410-3p by NEAT1.
methodsAn MTT assay was conducted to determine the half-maximal inhibitory concentration. The initial step was RNA isolation, which was performed after the cell culture. Then, cDNA synthesis was carried out for both miRNAs and lncRNAs to use RT-PCR to identify changes in RNA expression. Alterations in expression levels were measured by quantitative real-time polymerase chain reaction analyses. This web-based analysis was performed using the Student's t-test.
resultsAfter DOX treatment, NEAT1 expression levels decreased in human breast cancer (BC) cells, including MDA-MB231 and MCF-7. As expected, further expression than in cancer cell lines was detected in the normal mammary epithelial cell line MCF-10A. Simultaneously, miR410-3p expression levels exhibited an increase in BC cells. Our data demonstrated that NEAT1 expression was suppressed in cancer cells treated with doxorubicin, suggesting a potential therapeutic effect.
conclusionThese data indicate that DOX may affect BC lines via NEAT1, and that miR410-3p is effective in this pathway. Our data confirm the contribution of NEAT1 and miR410-3p to DOX treatment. Therefore, they can be used as a biomarker for the diagnosis and treatment of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.